$NNVC
Nanoviricides, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Shelton, CT
NNVC chart
What traders are saying about $NNVC
Latest postsNanoviricides, Inc. news
- NanoViricides Advances NV-387 Toward Phase II Trials for Measles
citybuzz - ·
- An Investigational Drug to Tackle Measles Outbreaks
Yahoo Finance ·
- NanoViricides, Inc. (NV3P.F) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Nanoviricides Inc (NV3P.MU) Seasonal returns chart
Yahoo Finance UK ·
- As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
Yahoo Finance ·
- NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Yahoo Finance ·
- Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Yahoo Finance ·
- NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
Yahoo Finance ·
- NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Yahoo Finance ·
- NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Yahoo Finance ·
- Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Yahoo Finance ·
- Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Yahoo Finance ·
Nanoviricides, Inc. key financials
| USD | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | -$8.2M | -$9.5M | -$8.3M | -$8.6M |
| Diluted EPS | $-0.41 | $-0.63 | $-0.70 | $-0.74 |
| Total assets (year end) | – | $12.3M | $11.6M | $13.4M |
| Cash and equivalents (year end) | – | $5.2M | $4.0M | $5.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Nanoviricides, Inc.
- Ticker
- NNVC (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Shelton, CT
- Incorporated in
- DE
- Fiscal year end
- June 30
- SEC CIK
- 1379006
Frequently asked questions
What exchange is Nanoviricides, Inc. listed on?
Nanoviricides, Inc. trades on the NYSE under the ticker symbol NNVC.
What industry is Nanoviricides, Inc. in?
Nanoviricides, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Nanoviricides, Inc. headquartered?
Nanoviricides, Inc.'s business address on file with the SEC is in Shelton, CT.
When does Nanoviricides, Inc.'s fiscal year end?
Nanoviricides, Inc.'s fiscal year ends on June 30.